REFERENCES
1. Röntgen, Ueber eine neue art von Strahlen, Wurzburg, 1896. Available from: https://www.sothebys.com/buy/e1f1e6ca-ae21-4a47-b628-71aea6ab12e6/lots/feb988bf-f908-49c1-bfea-4687612640df [Last accessed on 28 Aug 2023].
2. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
3. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
4. Ejtehadifar M, Shamsasenjan K, Movassaghpour A, et al. The effect of hypoxia on mesenchymal stem cell biology. Adv Pharm Bull 2015;5:141-9.
5. Hawkins KE, Sharp TV, McKay TR. The role of hypoxia in stem cell potency and differentiation. Regen Med 2013;8:771-82.
6. Imanirad P, Dzierzak E. Hypoxia and HIFs in regulating the development of the hematopoietic system. Blood Cells Mol Dis 2013;51:256-63.
7. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
8. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
9. Biologic basis of radiation oncology. 2015. Available from: https://clinicalgate.com/biologic-basis-of-radiation-oncology/ [Last accessed on 28 Aug 2023].
10. Kabakov AE, Yakimova AO. Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: approaches to targeting and radiosensitizing. Cancers 2021;13:1102.
11. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013;14:475-88.
12. Chen D, Cabay RJ, Jin Y, et al. MicroRNA deregulations in head and neck squamous cell carcinomas. J Oral Maxillofac Res 2013;4:e2.
14. Toustrup K, Sørensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22:119-27.
15. Toustrup K, Sørensen BS, Nordsmark M, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923-31.
16. Eustace A, Mani N, Span PN, et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res 2013;19:4879-88.
17. Kappler M, Kotrba J, Kaune T, et al. P4HA1: a single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients. Clin Transl Radiat Oncol 2017;5:6-11.
18. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 2004;14:233-40.
19. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
20. Hoskin PJ, Rojas AM, Phillips H, Saunders MI. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 2005;103:2287-97.
21. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:769-78.
22. Nijkamp MM, Span PN, Terhaard CH, et al. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial. Eur J Cancer 2013;49:3202-9.
23. Janssens GO, Rademakers SE, Terhaard CH, et al. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. Clin Cancer Res 2014;20:1345-54.
24. Grégoire V, Tao Y, Kaanders J, et al. OC-0278 Accelerated CH-RT with/without nimorazole for p16- HNSCC: the randomized DAHANCA 29-EORTC 1219 trial. Radiother Oncol 2021;161:S187-8.
26. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3:233-44.
27. Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 2012;49:24-40.
28. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
29. Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol 2012;48:1220-6.
30. Le QT, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 2008;27:351-62.
31. Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2018;4:CD005007.
32. Rischin D, Peters LJ, O’Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
33. Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122-9.
34. Hoover AC, Milhem MM, Anderson CM, et al. Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial. Head Neck 2015;37:722-6.
35. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108:479-85.
36. Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 1983;2:5-23.
38. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
39. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-77.
40. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-6.
41. Yang X, Knopp MV. Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol 2011;2011:732848.
42. Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging 2011;38:987-91.
43. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
44. Buch K, Fujita A, Li B, Kawashima Y, Qureshi MM, Sakai O. Using texture analysis to determine human papillomavirus status of oropharyngeal squamous cell carcinomas on CT. AJNR Am J Neuroradiol 2015;36:1343-8.
45. Fujita A, Buch K, Li B, Kawashima Y, Qureshi MM, Sakai O. Difference between HPV-positive and HPV-negative non-oropharyngeal head and neck cancer: texture analysis features on CT. J Comput Assist Tomogr 2016;40:43-7.
46. Vallieres M, Kumar A, Sultanem K, El Naqa I. FDG-PET image-derived features can determine hpv status in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2013;87:S467.
47. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674-87.
48. Servagi-Vernat S, Differding S, Sterpin E, et al. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study. Acta Oncol 2015;54:1008-16.
49. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010;97:172-5.
50. Jeong J, Setton JS, Lee NY, Oh JH, Deasy JO. Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiother Oncol 2014;111:340-7.
51. Leijenaar RT, Carvalho S, Hoebers FJ, et al. External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta Oncol 2015;54:1423-9.
52. Hatt M, Majdoub M, Vallières M, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015;56:38-44.
53. Zhang B, He X, Ouyang F, et al. Radiomic machine-learning classifiers for prognostic biomarkers of advanced nasopharyngeal carcinoma. Cancer Lett 2017;403:21-7.
54. Parmar C, Grossmann P, Rietveld D, Rietbergen MM, Lambin P, Aerts HJ. Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer. Front Oncol 2015;5:272.
55. Reuz S, Limkin E, Ou D, et al. A radiomic signature based on advanced tumor shape parameters (Spiculated-ness) to predict the outcome of locally advanced (LA) HNSCC patients. J Clin Oncol 2016;34:11571.
56. Scalco E, Fiorino C, Cattaneo GM, Sanguineti G, Rizzo G. Texture analysis for the assessment of structural changes in parotid glands induced by radiotherapy. Radiother Oncol 2013;109:384-7.
57. Scalco E, Moriconi S, Rizzo G. Texture analysis to assess structural modifications induced by radiotherapy. Annu Int Conf IEEE Eng Med Biol Soc 2015;2015:5219-22.
58. Pota M, Scalco E, Sanguineti G, et al. Early prediction of radiotherapy-induced parotid shrinkage and toxicity based on CT radiomics and fuzzy classification. Artif Intell Med 2017;81:41-53.
59. van Dijk LV, Langendijk JA, Zhai TT, et al. Delta-radiomics features during radiotherapy improve the prediction of late xerostomia. Sci Rep 2019;9:12483.
60. Abdollahi H, Chin E, Clark H, et al. Radiomics-guided radiation therapy: opportunities and challenges. Phys Med Biol 2022;67:12TR02.
61. Kann BH, Hicks DF, Payabvash S, et al. Multi-institutional validation of deep learning for pretreatment identification of extranodal extension in head and neck squamous cell carcinoma. J Clin Oncol 2020;38:1304-11.
62. Zhou Z, Wang K, Folkert M, et al. Multifaceted radiomics for distant metastasis prediction in head & neck cancer. Phys Med Biol 2020;65:155009.
63. Lu L, Lv W, Jiang J, et al. Robustness of radiomic features in [11C]choline and [18F]FDG PET/CT imaging of nasopharyngeal carcinoma: impact of segmentation and discretization. Mol Imaging Biol 2016;18:935-45.
64. Nikolov S, Blackwell S, Zverovitch A, et al. Clinically applicable segmentation of head and neck anatomy for radiotherapy: deep learning algorithm development and validation study. J Med Internet Res 2021;23:e26151.
65. Bagher-Ebadian H, Siddiqui F, Liu C, Movsas B, Chetty IJ. On the impact of smoothing and noise on robustness of CT and CBCT radiomics features for patients with head and neck cancers. Med Phys 2017;44:1755-70.
66. Park SY, Kim IH, Ye SJ, Carlson J, Park JM. Texture analysis on the fluence map to evaluate the degree of modulation for volumetric modulated arc therapy. Med Phys 2014;41:111718.
67. Bogowicz M, Pavic M, Riesterer O, et al. Targeting treatment resistance in head and neck squamous cell carcinoma - proof of concept for CT radiomics-based identification of resistant sub-volumes. Front Oncol 2021;11:664304.
68. Guidi G, Maffei N, Vecchi C, et al. A support vector machine tool for adaptive tomotherapy treatments: prediction of head and neck patients criticalities. Phys Med 2015;31:442-51.
69. Lam LHT, Do DT, Diep DTN, et al. Molecular subtype classification of low-grade gliomas using magnetic resonance imaging-based radiomics and machine learning. NMR Biomed 2022;35:e4792.
70. Kha QH, Le VH, Hung TNK, Le NQK. Development and validation of an efficient MRI radiomics signature for improving the predictive performance of 1p/19q Co-deletion in lower-grade gliomas. Cancers 2021;13:5398.
71. Caruso D, Polici M, Zerunian M, et al. Radiomics in oncology, part 1: technical principles and gastrointestinal application in CT and MRI. Cancers 2021;13:2522.
73. Brouwer CL, Steenbakkers RJ, Langendijk JA, Sijtsema NM. Identifying patients who may benefit from adaptive radiotherapy: Does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help? Radiother Oncol 2015;115:285-94.
74. Laskar SG, Swain M. HPV positive oropharyngeal cancer and treatment deintensification: how pertinent is it? J Cancer Res Ther 2015;11:6-9.
75. Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol 2017;18:202-11.
76. Torres-Roca JF, Eschrich S, Zhao H, et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005;65:7169-76.
77. Eschrich SA, Pramana J, Zhang H, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009;75:489-96.
78. Du Y, Peyser ND, Grandis JR. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther 2014;142:88-98.
79. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61:179-88.
80. Sano D, Matsumoto F, Valdecanas DR, et al. Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2011;17:1815-27.
81. Hsu HW, Wall NR, Hsueh CT, et al. Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol 2014;50:19-26.
82. Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011;10:1241-51.
83. Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 2009;20:1703-7.
84. de Bakker T, Journe F, Descamps G, et al. Restoring p53 function in head and neck squamous cell carcinoma to improve treatments. Front Oncol 2021;11:799993.
85. Chen RC, Gabriel PE, Kavanagh BD, McNutt TR. How will big data impact clinical decision making and precision medicine in radiation therapy? Int J Radiat Oncol Biol Phys 2016;95:880-4.
86. Jagsi R, Bekelman JE, Chen A, et al. Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys 2014;90:11-24.
87. Robertson SP, Quon H, Kiess AP, et al. A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients. Med Phys 2015;42:4329-37.
88. Marungo F, Robertson S, Quon H, et al. Creating a data science platform for developing complication risk models for personalized treatment planning in radiation oncology. In: 2015 48th Hawaii International Conference on System Sciences. Kauai, HI, USA; 5-8 January 2015; pp. 3132-40.
89. Cavalieri S, De Cecco L, Brakenhoff RH, et al. Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: the big data to decide EU project. Head Neck 2021;43:601-12.
90. Rosenstein BS, Capala J, Efstathiou JA, et al. How will big data improve clinical and basic research in radiation therapy? Int J Radiat Oncol Biol Phys 2016;95:895-904.
91. Willems SM, Abeln S, Feenstra KA, et al. The potential use of big data in oncology. Oral Oncol 2019;98:8-12.
92. Huser V, Cimino JJ. Impending challenges for the use of big data. Int J Radiat Oncol Biol Phys 2016;95:890-4.
93. Jairam V, Park HS. Strengths and limitations of large databases in lung cancer radiation oncology research. Transl Lung Cancer Res 2019;8:S172-83.
